logo.jpg
Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 12, 2022 09:30 ET | Processa Pharmaceuticals, Inc.
PCS12852 on target to complete enrollment by SeptemberExpanded efforts to increase enrollment in PCS499 and PCS6422 showing results HANOVER, Md., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Processa...
logo.jpg
Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST
August 05, 2022 15:00 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
logo.jpg
Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
August 04, 2022 09:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
logo.jpg
Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
August 03, 2022 16:00 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
logo.jpg
Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022
July 12, 2022 08:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD., July 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage biopharmaceutical company developing drugs to improve...
logo.jpg
Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 16:20 ET | Processa Pharmaceuticals, Inc.
Amended Next Generation Capecitabine study has restarted which will elucidate timelines for de novo formation of DPDExpanded efforts for enrollment in PCS499PCS12852 on target to complete enrollment...
logo.jpg
Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST
May 05, 2022 08:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
logo.jpg
Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)
April 20, 2022 08:30 ET | Processa Pharmaceuticals, Inc.
Processa focuses on identifying the PCS6422 regimens to increase capecitabine potency while identifying the MTD of Next Generation Capecitabine The amended protocol will provide a more precise...
logo.jpg
Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis
April 05, 2022 08:30 ET | Processa Pharmaceuticals, Inc.
Study will advance understanding of proper dosing while providing data to assist in the design of the next study for this >$1B marketExpect top line data at the end of 2022 HANOVER, MD, April ...
logo.jpg
Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
March 30, 2022 16:00 ET | Processa Pharmaceuticals, Inc.
Targeting Major Milestones 2022 HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing...